Celltrion stated on the 19th that its key product lines, including autoimmune disease treatments and anticancer drugs, continue to maintain high market shares in major Asian markets. In Malaysia, Singapore, and Thailand, the company is operating a direct sales system centered on local subsidiaries and expanding its sales activities in line with each country’s tender environment and healthcare system.

According to pharmaceutical market research firm IQVIA, as of the first quarter of 2026, the autoimmune disease treatment “Remsima” recorded a 93% market share in Singapore. It also maintained the top position in each market with 84% in Hong Kong, 78% in Thailand, and 72% in Malaysia.

The anticancer portfolio is also increasing its prescription share in major countries. The hematologic cancer treatment “Truxima” ranked first over the same period with a 93% market share in Singapore and 78% in Thailand. The breast and gastric cancer treatment “Herzuma” recorded a 51% share in Malaysia and 42% in Thailand.

In Malaysia, the growth of “Vegzelma,” a treatment for metastatic colorectal cancer and breast cancer, was particularly notable. Vegzelma ranked fourth among local bevacizumab products in terms of market share in the fourth quarter of last year, but rose to 30% in the first quarter of this year, becoming the market leader within a single quarter.

Celltrion cited its direct sales system via local subsidiaries as the driver of these results. In Asian markets where tender-based procurement accounts for a high proportion, stable product supply is a key factor for winning contracts and expanding prescriptions, and the company explained that it manages supply volumes in line with demand in each country.

The company is also conducting sales activities targeting local medical professionals. It participates in major academic conferences to present clinical data on its products and increase contact points with healthcare providers, while carrying out marketing that reflects each country’s medical environment and prescription characteristics.

The sales networks established with existing products are also expected to be used for the launch of follow-up products. In the second half of this year, Celltrion plans to launch the allergy treatment “Omlyclo” and the bone disease treatment “Stoboclo-Ossenbelt” in Thailand.

In Malaysia and Singapore, the company will introduce the autoimmune disease treatment “Steqima” within the year. Celltrion plans to leverage the networks of its local subsidiaries and medical institutions established through sales of existing products such as Remsima, Truxima, and Herzuma to accelerate market entry for new products.

As the number of products sold increases, a single sales organization can handle multiple products, enhancing the utilization of the direct sales network. Celltrion aims to maintain the market share of its existing biosimilars while adding sales of follow-up products, thereby simultaneously increasing both revenue scale and profitability in Asia.

In particular, recently launched follow-up products such as Omlyclo, Stoboclo-Ossenbelt, and Steqima are classified by the company as having higher profitability than existing products. Based on the market foundation secured by its existing portfolio, Celltrion plans to increase the sales share of these products and diversify the product mix of its Asian business.

A Celltrion official said, “Key products including Remsima are maintaining the No. 1 market share in major Asian countries,” adding, “The company will strengthen sales activities so that the performance of existing products can carry over to new products and will continue to expand performance growth in the Asian region.”

Popular News